139729-28-5

Basic information

• Product Name: 23-amino-3,6,9,12,15,18,21-heptaoxatricosanoic acid
• CAS NO: 139729-28-5
• Molecular Weight: 383.439
• Mol File: 139729-28-5.mol
• Article Data: 25

Chemical Properties

• Melting Point: 56-61°C
• Flash Point: >176 °C
• CAS DataBase Reference: 23-amino-3,6,9,12,15,18,21-heptaoxatricosanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 23-amino-3,6,9,12,15,18,21-heptaoxatricosanoic acid(139729-28-5)
• EPA Substance Registry System: 23-amino-3,6,9,12,15,18,21-heptaoxatricosanoic acid(139729-28-5)

Safety Data

• Hazardous Substances Data: 139729-28-5(Hazardous Substances Data)

Usage

Description

23-amino-3,6,9,12,15,18,21-heptaoxatricosanoic acid is a complex organic molecule characterized by its unique structure, which includes seven oxygen atoms and multiple amine groups. This molecule is known for its potential applications in various fields due to its versatile chemical properties.

Uses

Used in Bioconjugation:
23-amino-3,6,9,12,15,18,21-heptaoxatricosanoic acid is used as a bioconjugation agent for the formation of stable and functional bioconjugates. Its multiple amine groups facilitate the attachment of various biomolecules, such as proteins, peptides, or nucleic acids, enhancing their stability, solubility, and bioavailability.
Used in Drug Discovery:
23-amino-3,6,9,12,15,18,21-heptaoxatricosanoic acid is used as a lead compound in drug discovery for its potential therapeutic applications. Its unique structure and functional groups make it a promising candidate for the development of new drugs targeting various diseases and conditions.
Used in PEG-PLGA Drug Carrier Systems:
In the pharmaceutical industry, 23-amino-3,6,9,12,15,18,21-heptaoxatricosanoic acid is used as a component in PEG-PLGA drug carrier systems. Its hydrophobic/hydrophilic properties allow for the efficient encapsulation and controlled release of drugs, improving their biocompatibility, and reducing side effects.

Upstream product

• 134978-94-2 ethyl 2-<2-<2-(chloroethoxy)ethoxy>ethoxy>acetate 
• 112-60-7 Tetraethylene glycol 
• 172531-37-2 11-azido-3,6,9-trioxaundecanoic acid 
• 1446411-32-0 α-(2-azidoethyl)-ω-(carboxymethoxy)hexa(oxyethylene) 
• 352439-36-2 α-(2-azidoethyl)-ω-hydroxyhexa(oxyethylene) 
• 125274-16-0 1,1,1-triphenyl-2,5,8,11-tetraoxatridecan-13-ol 
• 168640-82-2 11-azido-3,6,9-trioxa-undecanyl p-toluenesulfonate 
• 86770-67-4 2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethanol 
• 77544-60-6 p-toluenesulfonic acid 2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl ester 
• 2615-15-8 pentaethylene glycol 
• 42749-28-0 toluene-4-sulfonic acid 2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl ester 
• 297162-49-3 tert-butyl 20-azido-3,6,9,12,15,18-hexaoxaeicosanoate 
• 880129-82-8 2-((17-azido-3,6,9,12,15-pentaoxaheptadec-1-yl)oxy)acetic acid 
• 86770-69-6 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol 

Downstream Products

• 139338-72-0 (2-{2-[2-((9H-fluoren-9-ylmethoxycarbonyl)amino)-ethoxy]-ethoxy}-ethoxy)-acetic acid 
• 166108-71-0 8-(9-fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid 
• 2097938-44-6 14-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]amino]-3,6,9,12-tetraoxatetradecanoic acid 
• 437655-95-3 [2-(2-{2-[2-((9H-fluoren-9-yl-methoxycarbonyl)amino)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-acetic acid 
• 1069067-08-8 2,2-dimethyl-4,13-dioxo-3,8,11,17,20-pentaoxa-5,14-diazadocosan-22-oic acid 

Relevant articles and documents

Preparation method of AEEA

The invention relates to the technical field of chemical synthesis, in particular to a preparation method of AEA. According to the preparation method of AEEA provided by the invention, amino on diglycol amine is protected by chloroacetyl chloride, then ring formation is carried out in the presence of NaH, and AEEA is obtained through hydrolysis. The method has the advantages of reduced reaction steps, low production cost, high product purity and few impurities, and is suitable for industrial large-scale production.

Optimization of IEDDA bioorthogonal system: Efficient process to improve trans-cyclooctene/tetrazine interaction

The antibody pretargeting approach for radioimmunotherapy (RIT) using inverse electron demand Diels-Alder cycloaddition (IEDDA) constitutes an emerging theranostic approach for solid cancers. However, IEDDA pretargeting has not reached clinical trial. The major limitation of the IEDDA strategy depends largely on trans-cyclooctene (TCO) stability. Indeed, TCO may isomerize into the more stable but unreactive cis-cyclooctene (CCO), leading to a drastic decrease of IEDDA efficiency. We have thus developed both efficient and reproducible synthetic pathways and analytical follow up for (PEGylated) TCO derivatives, providing high TCO isomeric purity for antibody modification. We have set up an original process to limit the isomerization of TCO to CCO before the mAbs’ functionalization to allow high TCO/tetrazine cycloaddition.

BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS

The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, FcyRI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy. Methods of treating disease states and/or conditions in which circulating proteins are associated with the disease state and/or condition are also described herein.